NTT Research partners with TUM on technologies to advance patient care
By Akshay Kedari  Date: 2019-11-13

NTT Research partners with TUM on technologies to advance patient care

NTT Research, Inc., has recently unveiled that its Medical and Health Informatics (MEI) Lab has signed a joint research agreement with the Technical University of Munich to work on three-dimensionally implantable and transformable electrodes.

A renowned medical researcher and scientist and director of the MEI Lab, Dr. Hitonobu Tomoike (M.D., Ph.D.) will be teamed up with Professor of Neuroelectronics, Dr. Bernhard Wolfrum at TUM in the Munich School of BioEngineering. The major scope of work for this multi-year project involves assembling 3D structures, screening and improving functional materials, and assessing biocompatibility.

Apparently, the NTT Research MEI Lab focuses on the miniaturization and transformation of medical device components. This mutual research will focus on the tendency of traditional electronics to work against and at a comparative distance from, instead of with and alongside the targeted organ or tissue.

The flexible micro- or nano-scale electrodes envisaged as a result of this project are anticipated to minimize the adverse impact that severe and planar electrode materials have on smooth and curvilinear biological samples.

According to Dr. Tomoike, with the aim to procure in-vivo biological signals stably and with a high-level accuracy for a longer time, a flexible electrode with higher biocompatibility is required. To attain this, the company will make use of micro-scale and nano conductive polymer thin films that are affable to living bodies and consider the use of in vivo implant electrodes, and also the control of structural change of the functional electrodes in the body.

Sources mentioned that this agreement also expands the goal of NTT Research of connecting with partners across the world. The MEI Lab is also planning to open an office in Germany. In the course of this project, MEI Lab will also send its two researchers to Munich. The research will formally launch in Q1 of 2020 and the first phase of the project may possibly take more than two years.
 

Source Credits: https://www.businesswire.com/news/home/20191112005536/en/NTT-Research-Technical-University-Munich-TUM-Enter

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...